retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Receptor Agonists Mounjaro: Retatrutide and Diabetes -
Description
o , Energy expenditure
134979-01-4, CH2COOH-PEG2-NH2.HCl References: [1] Gribble FM, Reimann F
Understanding the intricate relationship between payer control, channel distribution, and volume uptake can provide invaluable insights, not just within the diabetes and anti-obesity medicines (AOM) markets
This choice, which was based upon what was learned from recent global GLP-1 diabetes and obesity drug shortages, guarantees an ongoing and predictable supply of medicine to the Chinese patients, increases loyalty for the brand, and gives shareholders dependable revenue streams that are not impacted by geopolitical instability
Longer observational periods with larger cohorts are needed to further elucidate the role of GLP-1-RAs in treating IIH
